文献速递乳腺癌放疗

每周一次大分割全乳照射治疗早期乳腺癌的2期试验初步结果

First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-01

这项前瞻性2期试验评估了保乳术后每周一次大分割全乳放疗(WHBI)的早期结局。158例0-II期乳腺癌患者接受30或28.5 Gy/5次每周照射,中位随访3年,同侧乳腺肿瘤复发率1.3%,3年无病生存率97.5%,总生存率96.2%,急性毒性以1-2级为主,美容效果优良率82.3%。

要点

  • 保乳术后每周一次大分割全乳放疗的早期同侧复发率低(1.3%),生存结局良好。
  • 急性毒性以1-2级乳房疼痛、放射性皮炎和乏力为主,3级事件发生率1.3%。
  • 美容效果优良率为82.3%,从基线到末次随访发生显著美容改变的比例为11.6%。

核心结论

  • 保乳术后每周一次大分割全乳放疗的早期结局良好,与每日大分割全乳照射的结果相似。

研究设计与样本

  • 这是一项前瞻性单中心2期试验,纳入158例接受保乳术且切缘阴性的美国癌症联合委员会0、I或II期乳腺癌患者。
  • 患者接受全乳放疗30或28.5 Gy,分5次每周照射,可加或不加瘤床补量。
  • 入组标准与NSABP B39/RTOG 0413相同,对年龄、乳房大小、肿瘤分级、受体状态及细胞毒性化疗使用无限制。
  • 主要终点为同侧乳腺肿瘤复发,同时评估急性毒性(CTCAE 3.0版)、美容效果(哈佛量表)、远处转移和总生存。

主要发现

  • 中位年龄60岁(范围30-84岁),中位随访3年,同侧乳腺肿瘤复发2例(1.3%),其中1例合并广泛转移。
  • 远处转移4例(2.5%),3年无病生存率97.5%,总生存率96.2%。
  • 最常见1或2级急性毒性为乳房疼痛、放射性皮炎和乏力;3级事件2例(1.3%),分别为需麻醉性止痛药的疼痛和需住院的治疗后感染。
  • 美容效果优良 versus 一般或差的比例为82.3% versus 17.7%,从基线到末次随访美容效果从优良降至一般或差的比例为11.6%。

临床怎么用

  • 对于符合NSABP B39/RTOG 0413入组标准的早期乳腺癌保乳术后患者,每周一次大分割全乳放疗是可行的治疗选择,早期疗效和毒性可接受。

局限性

  • 随访时间较短(中位3年),美容稳定性及疾病特异性结局需继续随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report early outcome analysis of a prospective institutional phase 2 trial of weekly hypofractionated breast irradiation (WHBI) for patients undergoing breast-conserving surgery (BCS). METHODS AND MATERIALS: Patients who underwent BCS for American Joint Committee on Cancer stage 0, I, or II breast cancer with negative surgical margins received whole-breast radiation therapy to 30 or 28.5 Gy in 5 weekly fractions with or without an additional boost. The eligibility criteria were the same as for NSABP (National Surgical Adjuvant Breast and Bowel Project) B39/RTOG (Radiation Therapy Oncology Group) 0413, and there were no restrictions on age, breast size, tumor grade, receptor status, or the use of cytotoxic chemotherapy for otherwise eligible patients. The primary endpoint was ipsilateral breast tumor recurrence. Patients were also evaluated for acute toxicity (Common Terminology Criteria for Adverse Events version 3.0), cosmesis (Harvard Scale), development of distant metastatic disease, and overall survival. RESULTS: Between January 2011 and October 2015, 158 eligible patients underwent WHBI immediately following BCS. The median age was 60 years (range, 30-84 years), and the median follow-up period was 3 years. Ipsilateral breast tumor recurrence developed in a total of 2 patients (1.3%), 1 in conjunction with widespread metastatic disease. Distant metastatic disease developed in 4 patients (2.5%), and the 3-year disease-free survival and overall survival rates were 97.5% and 96.2%, respectively. The most common grade 1 or 2 acute toxicities were breast pain, radiation dermatitis, and fatigue. There were 2 grade 3 events (1.3%): pain requiring narcotic analgesics (1) and posttreatment infection requiring hospitalization (1). The rate of excellent or good cosmesis versus fair or poor cosmesis was 82.3% versus 17.7%. The rate of significant cosmetic change from baseline to last follow-up (dropping from excellent or good to fair or poor) was 11.6%. CONCLUSIONS: Early outcomes after WHBI are favorable and parallel those seen with daily hypofractionated whole-breast irradiation. With broader entry criteria than all previous reports of WHBI, this study will facilitate comparison to the results of NSABP B39/RTOG 0413. With continued follow-up, future reports will assess cosmetic stability and disease-specific outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Dragun AE, Ajkay NJ, Riley EC, et al. First Results of a Phase 2 Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581400. doi:10.1016/j.ijrobp.2017.01.212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。